Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.

ABSTRACT:

Introduction

Real-world data on the comparative effectiveness and safety of switching among different epoetins (including originators and biosimilars) are limited. In light of current debate about interchangeability, prescribers, some patient groups and decision makers are calling for additional post-marketing evidence on the clinical effects of switching between originator and biosimilar epoetins in chronic kidney disease (CKD) patients.

Objective

The objective of this study was to evaluate the effectiveness and safety of switching versus non-switching and of switching from originator/biosimilar epoetin alpha (ESA α) to any other epoetin in CKD patients.

Methods

An observational, record-linkage, multi-database, retrospective cohort study was carried out in four Itali

SUBMITTER: Belleudi V 

PROVIDER: S-EPMC6858470 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature